NJ Panel Refuses To Revive Fosamax 'Jaw Death' Suit

Law360, New York (March 25, 2013, 6:17 PM EDT) -- A New Jersey appeals court on Monday refused to revive the case of a woman who claimed Merck Sharp & Dohme Corp.'s osteoporosis drug Fosamax caused her to develop osteonecrosis of the jaw after a tooth extraction, rejecting her argument that the trial judge had wrongly excluded evidence.

A three-judge panel of the New Jersey Appellate Division said the trial judge properly excluded a 2010 Fosamax warning label, finding state rules barred using evidence of remedial measures taken immediately after an event to prove culpable conduct...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.